RxDoctor Payments Data

Katherine Barkei

Family · Oak Lawn, ILNPI 1457720682

Payments from drug & device makers

$3,622in general payments, 2019–2025

Across 83 payments — averaging $43.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$746
  • OPKO Pharmaceuticals, LLC$556
  • Amgen$464
  • Ardelyx, Inc.$339
  • Novo Nordisk$286
  • Bayer$257
  • plus $974 from 12 others

What the payments were for

  • Speaking & faculty fees$241%
  • Food & beverage$3,57299%
  • Education$261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,622 in reported general payments places this provider in the 90th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$3,097
Medicare patients
26
Services billed
29

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide44$96,930
XphozahTenapanor Hcl13$35,470
Sevelamer Carbonate56$15,491
LokelmaSodium Zirconium Cyclosilicate11$7,731
Midodrine Hcl27$3,098
Calcium Acetate20$2,340
ProsolParenteral Amino Acid 20% No.121$2,063
Nifedipine ErNifedipine46$1,949
Cinacalcet Hcl15$1,217
Atorvastatin Calcium62$785
Calcitriol53$639
Pantoprazole Sodium30$548
Amlodipine Besylate65$529
Hydralazine Hcl30$476
Metoprolol Succinate23$466

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$108$96,93044 claims
AstraZenecaLokelma$746$7,73111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,941 family providers in Illinois.

Other family in Oak Lawn

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →